Literature DB >> 8678969

Progression of metastases and symptom improvement from laparotomy in midgut carcinoid tumors.

C Makridis1, J Rastad, K Oberg, G Akerström.   

Abstract

A total of 121 consecutive patients with midgut carcinoid tumors underwent regular clinical control and 158 laparotomies for abdominal symptoms with 1 to 11 years (mean 5.2 years) of follow-up. Metastases were present in 93% of the patients at study inclusion and developed at initially uninvolved sites with an overall probability of 0.38. Patients without initial tumor spread developed mesenteric or liver metastases with the probability of 0.25 (mean delay 12 years), whereas those with mesenteric metastases exhibited a probability 0.56 to develop liver metastases (mean delay 6.1 years). Spread to extraabdominal sites in patients with mesenteric and liver metastases exhibited a probability of 0.22 (mean delay 4.3 years), and this spread was especially frequent (probability 0.60) in patients with only liver metastases at inclusion. Patients without the carcinoid syndrome (52%) mainly suffered from more or less episodic abdominal pain, nausea, and diarrhea. Marked mesenteric fibrosis detected at surgery (n = 59) generally was accompanied by symptoms of abdominal pain and weight loss, and it often required urgent intervention due to intestinal obstruction or ischemia. Complete or partial symptom alleviation was accomplished in 82% of the operated patients, and generally was most auspicious after primary acute or subacute procedures (n = 54). The complete or partial symptom improvements after surgery lasted for mean 5.3 years and tended to be longer after elective (n = 50) than acute operations. The findings substantiate encouraging results of laparotomy in a compromised cohort of patients with midgut carcinoid tumors. Because the patients also displayed a generally slow progression of metastases, liberal indications for laparotomy should prevail in symptomatic and possibly also asymptomatic individuals with midgut carcinoid tumors.

Entities:  

Mesh:

Year:  1996        PMID: 8678969     DOI: 10.1007/s002689900137

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  14 in total

Review 1.  Surgical treatment of gastrointestinal neuroendocrine tumors.

Authors:  Volker Fendrich; Detlef K Bartsch
Journal:  Langenbecks Arch Surg       Date:  2011-02-01       Impact factor: 3.445

2.  Partial abdominal evisceration and intestinal autotransplantation to resect a mesenteric carcinoid tumor.

Authors:  William H Kitchens; Nahel Elias; Lawrence S Blaszkowsky; A Benedict Cosimi; Martin Hertl
Journal:  World J Surg Oncol       Date:  2011-01-31       Impact factor: 2.754

Review 3.  Principles of diagnosis and management of neuroendocrine tumours.

Authors:  Michael J Raphael; David L Chan; Calvin Law; Simron Singh
Journal:  CMAJ       Date:  2017-03-13       Impact factor: 8.262

4.  Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center.

Authors:  Olov Norlén; Peter Stålberg; Kjell Öberg; John Eriksson; Jakob Hedberg; Ola Hessman; Eva Tiensuu Janson; Per Hellman; Göran Åkerström
Journal:  World J Surg       Date:  2012-06       Impact factor: 3.352

Review 5.  The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society.

Authors:  James R Howe; Kenneth Cardona; Douglas L Fraker; Electron Kebebew; Brian R Untch; Yi-Zarn Wang; Calvin H Law; Eric H Liu; Michelle K Kim; Yusuf Menda; Brian G Morse; Emily K Bergsland; Jonathan R Strosberg; Eric K Nakakura; Rodney F Pommier
Journal:  Pancreas       Date:  2017-07       Impact factor: 3.327

6.  Impairment of cognitive function reported by patients suffering from carcinoid syndrome.

Authors:  Anthony J Chambers; R Stewart Longman; Janice L Pasieka; Elijah Dixon; Otto Rorstad; Kathy Rach-Longman; Jean Jones
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

Review 7.  Extent of Lymph Node Dissection for Small Bowel Neuroendocrine Tumors.

Authors:  Julie Hallet; Calvin Law
Journal:  World J Surg       Date:  2020-07-31       Impact factor: 3.352

8.  Stenting of the superior mesenteric vein in midgut carcinoid disease with large mesenteric masses.

Authors:  Per Hellman; Ola Hessman; Göran Akerström; Peter Stålberg; Joakim Hennings; Martin Björck; L-G Eriksson
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

9.  Association of a Prophylactic Surgical Approach to Stage IV Small Intestinal Neuroendocrine Tumors With Survival.

Authors:  Kosmas Daskalakis; Andreas Karakatsanis; Ola Hessman; Heather C Stuart; Staffan Welin; Eva Tiensuu Janson; Kjell Öberg; Per Hellman; Olov Norlén; Peter Stålberg
Journal:  JAMA Oncol       Date:  2018-02-01       Impact factor: 31.777

Review 10.  The Landmark Series: Management of Small Bowel Neuroendocrine Tumors.

Authors:  Catherine G Tran; Scott K Sherman; James R Howe
Journal:  Ann Surg Oncol       Date:  2021-01-15       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.